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Background: The Malassezia yeasts which belong to the physiological microflora of human skin have also been
implicated in several dermatological disorders, including pityriasis versicolor (PV), atopic dermatitis (AD), and
psoriasis (PS). The Malassezia genus has repeatedly been revised and it now accommodates 14 species, all but one
being lipid-dependent species. The traditional, phenotype-based identification schemes of Malassezia species are
fraught with interpretative ambiguities and inconsistencies, and are thus increasingly being supplemented or
replaced by DNA typing methods. The aim of this study was to explore the species composition of Malassezia
microflora on the skin of healthy volunteers and patients with AD and PS.
Methods: Species characterization was performed by conventional, culture-based methods and subsequently
molecular techniques: PCR-RFLP and sequencing of the internal transcribed spacer (ITS) 1/2 regions and the D1/D2
domains of the 26S rRNA gene. The Chi-square test and Fisher’s exact test were used for statistical analysis.
Results: Malassezia sympodialis was the predominant species, having been cultured from 29 (82.9%) skin samples
collected from 17 out of 18 subjects under the study. Whereas AD patients yielded exclusively M. sympodialis
isolates, M. furfur isolates were observed only in PS patients. The isolation of M. sympodialis was statistically more
frequent among AD patients and healthy volunteers than among PS patients (P < 0.03). Whether this mirrors any
predilection of particular Malassezia species for certain clinical conditions needs to be further evaluated. The overall
concordance between phenotypic and molecular methods was quite high (65%), with the discordant results being
rather due to the presence of multiple species in a single culture (co-colonization) than true misidentification. All
Malassezia isolates were susceptible to cyclopiroxolamine and azole drugs, with M. furfur isolates being somewhat
more drug tolerant than other Malassezia species.
Conclusions: This study provides an important insight into the species composition of Malassezia microbiota in
human skin. The predominance of M. sympodialis in both normal and pathologic skin, contrasts with other
European countries, reporting M. globosa and M. restricta as the most frequently isolated Malassezia species.
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The fungi of the Malassezia genus, whose first descrip-
tion dates back to the middle of the XIX century, have
only recently gained considerable attention of the der-
matological community. This is because those basidio-
mycetous yeasts, being components of the microbiota of
human and animal skin and constituting up to 80% of
the total skin fungal population [1] are now increasingly
recognized as opportunistic pathogens resulting in dif-
ferent dermatological pathologies. Malassezia yeasts are
the causative agents of pityriasis versicolor (PV), which
is one of the commonest superficial mycoses in human
population worldwide [2]. Malassezia species are also
involved in the pathogenesis of various dermatoses
with global distribution, such as seborrheic dermatitis
(SD), atopic dermatitis (AD), and, more recently, psoria-
sis (PS) [3-6]. A growing number of reports demonstrate
the implication of Malassezia yeasts in other skin disor-
ders, including folliculitis, onychomycosis, confluent
and reticulated papillomatosis, and neonatal cephalic
pustulosis [7-10]. Finally, Malassezia yeasts have been
associated with systemic infections and outbreaks in
neonatal and immunocompromised adults intensive
care units [11,12].
The species content of the Malassezia genus has re-
peatedly been revised over the last two decades. In the
early 1990s the genus Malassezia contained only three
species, namely M. furfur, M. pachydermatis, and M.
sympodialis. In 1996, four other species (i. e. M. globosa,
M. obtusa, M. restricta, and M. slooffiae) were identified
within the genus, through a comparative sequence ana-
lysis of nuclear ribosomal DNA (rDNA) operons [13].
Since 2002 seven more new species have been described,
on the basis of molecular data: M. dermatis, M. equina,
M. japonica, M. nana, M. yamatoensis, M. caprae, and
M. cuniculi [14-19]. Overall, the genus Malassezia now
accommodates 14 species, all but one (M. pachydermatis)
being lipid-dependent species.
Among the Malassezia species, one of the most fre-
quently isolated is M. sympodialis, which has been con-
sidered to be associated with AD. One of the clearest
indications to support this is the fact that almost half of
the adult patients suffering from AD are sensitized to M.
sympodialis, as evidenced by allergen-specific IgE and/or
T-cell reactivity to the yeast, and that such reactivity is
rarely observed in other allergic diseases [20,21].
The identification of most of Malassezia species can
be achieved by using a combination of morphological,
biochemical, and physiological characteristics. The cur-
rently used protocol, based on the phenotypic criteria,
includes the examination of colony and cell morphology,
determination of urease, catalase, and β-glucosidase ac-
tivities, growth at 37°C and 40°C, and the capacity to
grow with different polyoxyethylene sorbate compounds(Tween 20, 40, 60, 80) and polyoxyethylene castor oil
(Cremophor EL), as the sole lipid source [22].
With the advent of molecular biology tools, several
new, DNA-targeted methods have been developed and
tested for species identification within the Malassezia
taxon. These include pulsed-field gel electrophoresis
(PFGE) [23,24], randomly amplified polymorphic DNA
(RAPD) analysis [23,25], amplified fragment length
polymorphism (AFLP) analysis [25,26], denaturing gra-
dient gel electrophoresis (DGGE) [25], multilocus en-
zyme electrophoresis (MEE) [27], PCR-based single
strand confirmation polymorphism (PCR-SSCP), PCR-
based restriction fragment length polymorphism (PCR-
RFLP) [7,28-34], nested PCR [32,35-37], real-time (RT)
PCR [35,38], and direct sequencing of various genetic
loci, such as rDNA and internal transcribed spacer
(ITS) 1 and 2 regions in particular, the chitin synthase
(CHS2) gene, and the RNA polymerase subunit 1 (RPB1)
gene [18,26,39-41].
The purpose of this study was to explore the species
composition of Malassezia microflora on the skin of
healthy volunteers and patients with AD and PS. Species
determination was performed by using both conven-
tional, culture-based methods and molecular techniques,
that is PCR-RFLP and direct sequencing targeting the
rDNA cluster of the Malassezia genome.Methods
Subjects
The study group comprised of 18 subjects (8 (44.4%) males
and 10 (55.6%) females, aged from 22–70 years; mean age:
34.8 years; median age: 30 years), all being Polish and liv-
ing in the Lesser Poland province. The subjects were split
into three, equally sized groups (i.e. six subjects per each
group), consisting of healthy volunteers (i) and patients di-
agnosed with either atopic dermatitis (ii) or psoriasis (iii).
Both AD and PS patients were recruited from the routine
dermatology outpatient clinic at the Collegium Medicum
of the Jagiellonian University in Kraków, where they were
assessed clinically and received treatment during a 3-year
period (2008–2010). The diagnosis of AD was made ac-
cording to the Hanifin-Rajka criteria [42], and the severity
of the disease was categorized based on the Severity
Scoring of Atopic Dermatitis (SCORAD) index [43]. The
diagnosis of PS was based on clinical features and
confirmed by histopathological analysis. The severity of
psoriatic lesions was evaluated using the Body Surface
Area (BSA) and Psoriasis Area and Severity (PASI) in-
dexes [44,45].
Information on demographic characteristics and clin-
ical aspects of the disease were collected in a standard-
ized questionnaire by reviewing the medical records and
analysed (Table 1).















1. TK AD Head M 24 37 R 24 Topical; sys:
antihistaminics
Positive No 40.10.I. M. sympodialis
2. Face 40.10.II. M. sympodialis
3. Back 40.10.IV. M. sympodialis
4. MP Head F 28 31 R 23 Topical; sys:
antihistaminics
Positive Rhinoconjunctivitis 8.11.I. M. sympodialis
5. Chest 8.11.III. M. sympodialis + C. d.*
6. Back 8.11.IV. M. sympodialis
7. DJ Chest M 29 34.6 R 29 Topical; sys:
antihistaminics
Positive Rhinoconjunctivitis 27.10.III. M. sympodialis
8. Back 27.10.IV. M. sympodialis
9. JW Chest F 22 10.2 R 22 Topical; sys:
antihistaminics
Positive No 7.11.III. M. sympodialis
10. Back 7.11.IV. M. sympodialis
11. MB Back M 22 39.4 R 22 Topical; sys:
antihistaminics
Negative 25.10.IV. M. sympodialis
12. EP Back F 31 10.2 R 31 Topical; sys:
antihistaminics
Negative Vitiligo 17.10.IV. M. sympodialis
13. BT PS Head F 50 8.2 R 20 Topical; sys: CyA Positive No 10.11.I. M. sympodialis




16. Back 10.11.IV. M. sympodialis
17. BH Face F 44 10 R 15 Topical Negative No 45.08.II. M. furfur
18. Chest 45.08.III. M. furfur +M.
sympodialis
19. SK Back M 38 3.6 R 5 Topical; sys: CS Negative No 20.09.IV. M. furfur +M.
sympodialis
20. EN Back F 31 6.6 R 5 Topical Negative No 17.09.IV. M. sympodialis
21. KK Face M 23 11.2 R 12 Topical; sys: CyA Positive No 43.08.II. M. furfur
22. MB Back F 29 5.7 R 15 Topical Positive No 6.11.IV. M. sympodialis
23. MT Control Head F 31 No 1.11.IA. M. globosa
24. Face 1.11.II. M. globosa +M.
restricta
25. Chest 1.11.IIIA. M. sympodialis
26. Back 1.11.IVA. M. sympodialis


















Table 1 Characteristics of 18 subjects under the study and microbiological details of 35 isolated Malassezia species (Continued)
28. Back 69.09.IV. M. slooffiae +M.
sympodialis
29. BP Chest M 69 No 67.09.III. M. sympodialis
30. Back 67.09.IV. M. sympodialis
31. PK Chest M 27 No 68.09.III. M. sympodialis
32. Back 68.09.IV. M. sympodialis
33. MS Chest F 28 No 2.11.III. M. sympodialis
34. Back 2.11.IV. M. sympodialis
35. JP Back F 31 No 12.09.IV. M. sympodialis
aPatient initials.
bThree subject groups under investigation: (i) patients with atopic dermatitis (AD), (ii) patients with psoriasis (PS), and (iii) healthy volunteers (control).
cM, male; F, female.
dThe numbers represent the SCORAD index values in AD patients, or the PASI index values in psoriatic patients.
eR, recurrent.
fTopic treatment for AD patients included emolients, corticosteroids, tacrolimus, pimecrolimus, antibiotics, whereas topic treatment for psoriatic patients included corticosteroids, calcipotriol, tacrolimus, pimecrolimus,
emollients; CS, corticosteroids; CyA: Cyclosporine A; sys., systemic.
gBased on direct interviewing of the patients.
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From each patient, four samples originating from four
different anatomical sites of the body, that is the scalp,
face, chest (interclavicle region) and back (interscapular
region) were collected by a standard swab method. A
sterile cotton swab soaked with sterile saline was used to
rub against the skin surface, with continuous rotation of
the swab and over at least 15 seconds, and immediately
streaked evenly onto modified Dixon’s agar (mDA)
medium.
Culture conditions and yeast strains
The yeasts were cultured on mDA plates at 32°C, with
growth being monitored every day for two weeks. The
suspected colonies of Malassezia sp. were subcultured,
by streaking onto mDA slants, and subjected to the
identification procedures described hereafter. The cul-
tures were maintained by weekly passaging on fresh
mDA slants.
Apart from the Malassezia sp. strains isolated from
clinical samples, six reference strains representing as
many Malassezia species (Malassezia furfur CBS 6001;
M. globosa CBS 7966; M. obtusa CBS 7876; M. slooffiae
CBS 7956; M. restricta CBS 7877; M. sympodialis CBS
7222) and purchased from the CBS (Centraalbureau
voor Schimmelcultures, Utrecht, The Netherlands) cul-
ture collection were included in the study.
Drug susceptibility testing
In vitro susceptibility testing was performed by using
commercially available Neo-Sensitabs diffusion assays
(Neo-Sensitabs, Rosco Diagnostica, Denmark), according
to the instructions provided by the manufacturer and
following the Clinical and Laboratory Standards Institute
(CLSI) guidelines [46] with some modifications. Colonies
from a seven-day yeast culture, grown on mDA, were
scraped off and suspended in sterile saline with sterile
glass beads. The suspension was mixed vigorously for
30 seconds in a vortex mixer, and adjusted to a turbidity
equivalent of a 5.0 McFarland standard. The so prepared
inoculum was swabbed over the mDA plates. After
allowing the plates to dry completely, Neo-Sensitabs tab-
lets containing 50 μg of ciclopirox (CPO), 25 μg of flu-
conazole (FLZ), 15 μg of ketoconazole (KTZ), 10 μg of
econazole (ECZ), 10 μg of miconazole (MNZ), and 8 μg
of itraconazole (ITZ) were applied onto the surface and
the plates were incubated at 32°C, with reading taken
after 48 and 72 h. The zones of inhibition were mea-
sured at a point in which either there was prominent re-
duction of growth or no visible growth occurred. Since
the interpretation of antifungal resistant/susceptible cat-
egories among the Malassezia species has not yet been
established, interpretive criteria for the yeasts reported
by the CLSI [46] and provided by the manufacturer ofthe Neo-Sensitabs were employed. Accordingly, resist-
ance was assumed if the inhibition zone was less than
10 mm for ITZ, less than or equal to 11 mm for CPO,
ECZ, and MNZ, less than or equal to 14 mm for FLZ,
and less than or equal to 22 mm for KTZ.
To validate the performance of the Neo-Sensitabs drug
susceptibility testing, two quality control (QC) strains
were used: Pichia kudriavzevii (teleomorph of Candida
krusei) DBVPG 7235 (corresponding to ATCC 6258) and
Candida parapsilosis DBVPG 6150 (corresponding to
ATCC 22019), from the Industrial Yeasts Collection
DBVPG (Perugia, Italy).
All Malassezia strains were tested in duplicate. Also,
the QC strains were assayed twice.
DNA isolation
Genomic DNA extraction was done from pure cultures.
Briefly, a few yeast colonies were suspended in 200 μL of
TE buffer (10 mM Tris–HCl [pH 8.0], 1 mM EDTA)
and subjected to 3 rounds of sonication (three sonication
cycles of 15 s each separated by 15 s intervals) in ice
water bath, at 20% amplitude in a Vibra Cell sonicator
(Sonics & Materials Inc., USA). The obtained homogen-
ate was further processed with the Genomic Mini AX
Yeast kit (A&A Biotechnology, Poland) following the
manufacturer’s instructions.
Species identification
Identification by phenotypic methods
All yeast cultures were identified to species level by using
conventional mycological methods, including examination
of colonial and microscopic morphologies (i.e. colonies’
shape, texture, and colour, and cell size, shape and budding
characteristics) as well as physiological and biochemical
tests, including assimilation of Tween 20, 40, 60, and 80, as-
similation of Cremophor EL, catalase reaction, cleavage of
esculin, and growth at 37°C. Phenotypic feature testing was
performed essentially as described elsewhere [47], and the
characteristics table of Malassezia spp. provided by Ashbee
and Evans [48] served as the species identification key.
Molecular analysis
Molecular identification involved PCR-RFLP analysis
along with sequence analysis of different nuclear loci
within the rDNA operon of Malassezia spp., including
the ITS1 and ITS2 regions and the D1 and D2 domains
of the 26S rRNA gene.
PCR-RFLP analysis
Two PCR-RFLP assays, targeting the ITS2 region and par-
tial 26S rRNA gene, were performed, as described previ-
ously [28,29], with slight modifications. Briefly, primers
ITS3 (5′-GCATCGATGAAGAACGCAGC-3′) and ITS4
(5′-TCCTCCGCTTATTGATATGC-3′) were used to
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AGCGGAGGAAAAGAAACT-3′) and Maldown (5′-
GCGCGAAGGTGTCCGAAG-3′) were used to amplify
the 26S rRNA gene fragment (Figure 1). PCR mixtures
were prepared by using the TopTaq Master Mix kit
(QIAGEN, Germany) in a total volume of 25 μL, con-
taining 2× TopTaq Master Mix (final conc. 1×; the mix
contains 1.25 U of Taq DNA polymerase, 200 μM each
deoxyucleoside triphosphate, and 1× PCR buffer with
1.5 mM MgCl2), 0.4 μM each primer, and 1 μL (ca. 10–
20 ng) of template DNA. The PCR conditions were as
follows: 94°C for 3 min, 30 cycles at 94°C for 30 s, 50°C
for 30 s, and 72°C for either 30 s (ITS2) or 50 s (26S
rDNA), and a final step at 72°C for 10 min. After con-
firmation of the presence of the amplicons of correct
sizes with gel electrophoresis, the purified PCR prod-
ucts of the ITS2 and 26S rDNA regions were subjected
to RFLP analysis with AluI and HaeII enzymes, respect-
ively. Restriction reactions were carried out in 20 μL vol-
umes containing 8 μL (ca. 200 ng) of PCR product and 1
U of the restriction enzyme together with the appropriate
reaction buffer (final conc. 1×) at 37°C for 45 min (FastDi-
gest restriction enzymes; Fermentas UAB, Lithuania). Re-
striction patterns were compared with those of reference
Malassezia strains and virtual, species-specific patterns
established in the original publications [28,29].
PCR-sequencing
Sequencing of the ITS1 and ITS2 regions and the D1/
D2 domains of the 26S rRNA gene was performed,
as reported earlier [26]. In short, primers V9 (5′-
TGCGTTGATTACGTCCCTGC-3′) and RLR3R (5′-
GGTCCGTGTTTCAAGAC-3′) amplified a fragment
encompassing ITS1, the 5.8S rRNA gene, ITS2, and
partial regions of the 18S and 26S rDNA (Figure 1).
The PCR was carried out in a 25-μL reaction volume
containing 2× TopTaq Master Mix (final conc. 1×)
(QIAGEN, Germany), 0.5 μM each primer, and 1 μL (ca.
20 ng) of template DNA. The thermal cycling profile
was 94°C for 5 min, 30 cycles at 94°C for 45 s, 56°C for
30 s, and 72°C for 1.5 min, and a final step at 72°C for
10 min. The resulting amplicons were electrophoresed
to verify the presence of a single product of the correct
size, purified, and sequenced either directly or after clon-
ing into a plasmid vector using the pGEM-T Easy Vector
system (Promega, USA), according to the vendor’s proto-
col, when initial sequence information showed the pos-
sible presence of two (or more) different species.
The primers used in the sequence reaction were ITS4
(5′-TCCTCCGCTTATTGATATGC-3′) and ITS5 (5′-
GGAAGTAAAAGTCGTAACAAGG-3′) for analysis of
the ITS1/ITS2, and NL1 (5′-GCATATCAATAAGCG-
GAGGAAAAG-3′) and RLR3R for analysis of the D1/
D2 domains of the 26S rRNA gene (Figure 1).Forward and reverse sequences were assembled and edi-
ted with ChromasPro ver. 1.7.1 (Technelysium, Australia)
and the resulting consensus sequences were searched
against the GenBank database of the National Center for
Biotechnology Information (NCBI) using the BLASTN al-
gorithm (http://blast.ncbi.nlm.nih.gov/).
Distance scores of up to 1.00% (99% match) were used
as a proxy for species identity, and the species giving the
closest match was considered the correct identification.
The nucleotide sequences determined in the study
were deposited in the GenBank database (NCBI) under
the accession numbers listed in Table 2.Statistical analysis
The Chi-square test and Fisher’s exact test were used to
evaluate the differences in the frequency and distribution
of Malassezia species between the AD patients, PS pa-
tients, and healthy subjects. A P value < 0.05 was consid-
ered statistically significant.Ethics
The study was approved by the Ethics Committee of the
Jagiellonian University in Kraków. All the patients gave
informed consent to participate in the study.Results
A total of 35 Malassezia sp. cultures were obtained from
clinical samples, with back being the most frequent site
of isolation (16 cultures; 45.7% of all Malassezia cul-
tures), followed by chest (10; 28.6%), face (5; 14.3%), and
head (4; 11.4%). Of 24 skin samples collected from each
of the three subject groups, 13 (54.2%), 12 (50%), and 10
(41.7%) gave positive culture in the control group, AD
group, and PS group, respectively. The overall positive
culture rate of the Malassezia yeasts from 4 different
body sites of 18 patients under the study was 48.6% (35
positive samples out of 72 samples tested).Phenotypic identification
Based on conventional, phenotypic methods, all 35 yeast
cultures were initially separated into 5 different Malassezia
species. There were recognized 19 (54.3%) M. sympodialis,
7 (20%) M. furfur, 5 (14.3%) M. slooffiae, 2 (5.7%) M. glo-
bosa, and 2 (5.7%) M. obtusa isolates. Among the isolates
from AD patients and healthy volunteers, M. sympodialis
predominated and accounted for 66.7% (8/12) and 46.1%
(6/13) of the isolates, respectively. In both these groups
there were isolates of other four (control group) or three
(all but M. globosa) species (AD group). In psoriatic patient
group, only two species, equally abundant, were identified,
namely M. sympodialis and M. furfur.
Figure 1 Schematic representation of the rDNA operon in Malassezia yeasts. The loci under analysis are depicted. Major rRNA genes are
shown as grey boxes. Primers used for PCR amplification of the target DNA sequences and those used for sequencing are indicated as white and
black block arrows, respectively. Loci analysed by PCR-RFLP or direct sequencing are shown as black or white rectangles, respectively, and are
designated after the primers used for their amplification (or sequencing). LSU, large subunit (rRNA); SSU, small subunit (rRNA); IGS, intergenic
spacer region; ITS, internal transcribed spacer.
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PCR amplification of the partial 26S rRNA gene pro-
duced, for all isolates, a single amplicon of the expected
size of ca. 550 bp. Upon digestion of the amplified prod-
ucts with the HaeII restriction enzyme 4 different re-
striction patterns could be distinguished. Three of them
matched exactly the HaeII restriction patterns predicted
for M. sympodialis (26 isolates; 74.3% of all isolates), M.
furfur or M. slooffiae (6; 17.1%), and M. globosa or M.
restricta (2; 5.7%). For one isolate (20.09.IV.) a mixed
HaeII restriction pattern was obtained, corresponding to
M. sympodialis and M. furfur or M. slooffiae.
A single amplicon of ca. 400–500 bp in size was gener-
ated by PCR amplification of the ITS2 region for all
Malassezia isolates except one (20.09.IV.), for which two
PCR products were visualized (one of ca. 400 bp and an-
other of ca. 500 bp). When the PCR products were
digested with the AluI restriction enzyme 6 different re-
striction patterns were demonstrated, 4 of which corre-
sponded to those expected for M. sympodialis (24 isolates;
68.6% of all isolates), M. furfur (4; 11.4%), M. slooffiae (2;
5.7%), and M. globosa (1; 2.9%). The restriction pattern of
one isolate (1.11.II.) was a combination of those forM. glo-
bosa and M. restricta. The restriction patterns of 2 isolates
(10.11.II.; 8.11.III.) contained a fragment characteristic of
M. sympodialis, along with two additional fragments
whose sizes did not correlate with the sizes of the AluI re-
striction fragments previously reported for Malassezia
species. In case of one isolate, for which two PCR products
were obtained, they were both purified by gel extraction
and subjected to AluI digestion separately (20.09.IV.A/B).
This resulted in 2 single restriction profiles, conforming to
that of M. sympodialis and of M. furfur.
Based on the results from two PCR-RFLP assays, 31
(88.6%) of the isolates tested could be separated into 4distinct Malassezia species, namely, M. sympodialis (24
isolates; 68.6% of all isolates), M. furfur (4; 11.4%), M.
slooffiae (2; 5.7%), and M. globosa (1; 2.9%). Two isolates
were identified as a mixture of two different Malassezia
species, that is M. sympodialis and M. furfur (20.09.IV.)
and M. globosa and M. restricta (1.11.II.). Finally, 2 iso-
lates (10.11.II.; 8.11.III.) appeared to represent M. sympo-
dialis mixed with another unknown fungal species.
PCR-sequence analysis
The rDNA region containing the ITS1/ITS2 sequences
and D1/D2 domains of the 26S rRNA was successfully
amplified, for all isolates tested, resulting in a sole prod-
uct of ca. 1,500 bp. The purified PCR products were
used as templates in two independent sequencing reac-
tions, targeting the ITS and D1/D2 loci, respectively.
Upon ITS1/ITS2 sequence analysis, 33 (94.3%) of the
isolates tested, could be unambiguously identified at the
species level. The consensus ITS sequences of those iso-
lates shared ≥99% similarity with the sequences of previ-
ously characterized fungal species, as evidenced by the
BLAST search of the GenBank database. Twenty-four
(68.6% of all isolates) isolates had a 100% similarity with
the sequence of M. sympodialis. Four (11.4%) isolates
showed 100% sequence identity with M. furfur, and 2
(5.7%) isolates showed 99% sequence similarity with M.
slooffiae. The ITS1/ITS2 sequences of 2 isolates desig-
nated 8.11.III and 10.11.II., formerly identified as M.
sympodialis (on PCR-RFLP analysis) showed a complete
match (100% identity) to the ITS1/ITS2 sequences of
Cryptococcus diffluens and Aureobasidium proteae/pull-
ulans), respectively. The results for those two isolates
were consistent, even if sequencing was performed on
PCR products from different PCR runs using DNA from
three different isolations. Sequence analysis of the ITS
Table 2 Species identification results obtained upon phenotypic testing and molecular typing of 35 Malassezia cultures
Strain
no.















1. 40.10.I. M. slooffiae M. sympodialis KC141968 M. sympodialis
MA 73
100% KC415092 M. sympodialis
IFM 48109
100% M. sympodialis
2. 40.10.II. M. slooffiae M. sympodialis KC141969 M. sympodialis
CBS 7222
100% KC415093 M. sympodialis
IFM 48109
100% M. sympodialis
3. 40.10.IV. M. sympodialis M. sympodialis KC141970 M. sympodialis
CBS 7222
100% KC415094 M. sympodialis
IFM 48109
100% M. sympodialis
4. 8.11.I. M. obtusa M. sympodialis KC152895 M. sympodialis
CBS 7222
100% KC415085 M. sympodialis
IFM 48109
100% M. sympodialis
5. 8.11.III. M. furfur M. sympodialis KC152904 C. diffluens CBS
160
100% KC241877 C. diffluens CBS
6436
100% M. sympodialis+ C. d.*
6. 8.11.IV. M. sympodialis M. sympodialis KC152896 M. sympodialis
CBS 7222
100% KC415086 M. sympodialis
IFM 48109
100% M. sympodialis
7. 27.10.III. M. sympodialis M. sympodialis KC141966 M. sympodialis
MA 73
100% KC415095 M. sympodialis
IFM 48109
100% M. sympodialis
8. 27.10.IV. M. sympodialis M. sympodialis KC141967 M. sympodialis
MA 73
100% KC415096 M. sympodialis
IFM 48109
100% M. sympodialis
9. 7.11.III. M. sympodialis M. sympodialis KC152893 M. sympodialis
CBS 7222
100% KC415083 M. sympodialis
IFM 48109
100% M. sympodialis
10. 7.11.IV. M. sympodialis M. sympodialis KC152894 M. sympodialis
MA 73
100% KC415084 M. sympodialis
IFM 48109
100% M. sympodialis
11. 25.10.IV. M. sympodialis M. sympodialis KC119577 M. sympodialis
CBS 7222
100% KC415097 M. sympodialis
IFM 48109
100% M. sympodialis
12. 17.10.IV. M. sympodialis M. sympodialis KC119576 M. sympodialis
CBS 7222
100% KC415098 M. sympodialis
IFM 48109
100% M. sympodialis
13. 10.11.I. M. sympodialis M. sympodialis KC152897 M. sympodialis
CBS 7222
100% KC415087 M. sympodialis
IFM 48109
100% M. sympodialis
14. 10.11.II. M. sympodialis M. sympodialis KC152905 A. pullulans
CPC 13701
100% KC241878 A. pullulans
RA406
100% M. sympodialis+ A. p.**
15. 10.11.IIIA. M. furfur M. furfur KC152897 M. furfur M235 100% KC415088 M. furfur VG Ig
02
99% M. furfur
16. 10.11.IV. M. sympodialis M. sympodialis KC152901 M. sympodialis
CBS 7222
100% KC415091 M. sympodialis
IFM 48109
100% M. sympodialis
17. 45.08.II. M. furfur M. furfur KC141972 M. furfur M235 100% KC415099 M. furfur VG Ig
02
100% M. furfur
18. 45.08.III. M. furfur M. furfur KC141973 M. sympodialis
CBS 7222
100% KC415100 M. sympodialis
IFM 48109
99% M. furfur +M.
sympodialis
19. 20.09.IV. M. furfur M. furfur + M.
sympodialis
KC141965 M furfur M235 100% KC415101 M. furfur VG Ig
02
99% M. furfur +M.
sympodialis
20. 17.09.IV. M. sympodialis M. sympodialis KC109788 M. sympodialis
MA 73
100% KC415102 M. sympodialis
IFM 48109
100% M. sympodialis
21. 43.08.II. M. furfur M. furfur KC141971 M. furfur M235 100% KC415103 M. furfur VG Ig
02
100% M. furfur
22. 6.11.IV. M. sympodialis M. sympodialis KC152892 M. sympodialis
MA 73
100% KC415082 M. sympodialis
IFM 48109
100% M. sympodialis
23. 1.11.IA. M. globosa M. globosa KC152884 M. globosa CBS
7966
96% KC415074 M. sympodialis
IFM 48109
100% M. globosa




99% KC415075 M. sympodialis
IFM 48109
100% M. globosa +M.
restricta
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Table 2 Species identification results obtained upon phenotypic testing and molecular typing of 35 Malassezia cultures
(Continued)
25. 1.11.IIIA. M. sympodialis M. sympodialis KC152886 M. sympodialis
MA 73
100% KC415076 M. sympodialis
IFM 48109
100% M. sympodialis
26. 1.11.IVA. M. furfur M. sympodialis KC152888 M. sympodialis
MA 73
100% KC415078 M. sympodialis
IFM 48109
100% M. sympodialis
27. 69.09.III. M. slooffiae M. slooffiae KC141978 M. slooffiae CBS
7956
99% KC415104 M. slooffiae
sc7LG
99% M. slooffiae
28. 69.09.IV. M. slooffiae M. slooffiae KC141979 M. slooffiae CBS
7956
99% KC415105 M. sympodialis
IFM 48109
100% M. slooffiae +M.
sympodialis
29. 67.09.III. M. sympodialis M. sympodialis KC141974 M. sympodialis
CBS 7222
100% KC415106 M. sympodialis
IFM 48109
100% M. sympodialis
30. 67.09.IV. M. slooffiae M. sympodialis KC141975 M. sympodialis
CBS 7222
100% KC415107 M. sympodialis
IFM 48109
100% M. sympodialis
31. 68.09.III. M. sympodialis M. sympodialis KC141976 M. sympodialis
CBS 7222
100% KC415108 M. sympodialis
IFM 48109
100% M. sympodialis
32. 68.09.IV. M. sympodialis M. sympodialis KC141977 M. sympodialis
CBS 7222
100% KC415109 M. sympodialis
IFM 48109
100% M. sympodialis
33. 2.11.III. M. sympodialis M. sympodialis KC152890 M. sympodialis
MA 73
100% KC415080 M. sympodialis
IFM 48109
100% M. sympodialis
34. 2.11.IV. M. obtusa M. sympodialis KC152891 M. sympodialis
MA 73
100% KC415081 M. sympodialis
IFM 48109
100% M. sympodialis
35. 12.09.IV. M. sympodialis M. sympodialis JX915741 M. sympodialis
MA 73
100% KC415110 M. sympodialis
IFM 48109
100% M. sympodialis
aIdentification algorithm included macro- and microscopic examination of fungal colonies along with biochemical tests, as described in the Materials and
Methods section.
bBased on two PCR-RFLP assays (i. e. with AluI and HaeII restriction endonucleases).
cResults of BLAST search of GenBank (http://blast.ncbi.nlm.nih.gov/); The ITS and D1/D2 accession numbers are those under which the respective sequences
determined in this study can be found in the GenBank; Percentage similarities with ITS or D1/D2 sequences deposited in the GenBank are given.
dBased on combined molecular methods results; *C. d., Cryptococcus diffluens; **A. p., Aureobasidium pullulans.
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of M. globosa and M. restricta by PCR-RFLP analysis,
was informative only after subcloning of the PCR prod-
uct into the pGEM-T plasmid. Although several recom-
binants were examined, each time the ITS sequence
homologous (99% identity) to that of M. restricta was re-
solved. Interestingly, when applying the same procedure
(i. e. sequence analysis from the pGEM-T vector) to the
second isolate (20.09.IV.) that was identified as consist-
ing of two different Malassezia species (M. furfur and
M. sympodialis), only a sequence with 100% similarity
with that of M. furfur could be revealed. Two isolates
designated 2.11.III. and 1.11.IA. yielded ITS1/ITS2 se-
quences with <99% similarity with the closest sequence
in the GenBank database; the former gave the closest se-
quence match to M. sympodialis, whereas the latter – to
M. globosa, at a similarity level of 97% and 96%, respect-
ively (Table 2).
Sequence analysis of partial 26S rRNA gene allowed
clear species discrimination of all isolates tested. The se-
quences of 33 (94.3%) isolates displayed ≥99% sequence
identity to 4 Malassezia species strains, namely M. sym-
podialis (26 isolates; 74.3% of all isolates), M. furfur (4;
11.4%), M. globosa (2; 5.7%), and M. slooffiae (1; 2.9%).
Finally, two isolates had a perfect match (100% sequenceidentity), one for C. diffluens, and the other for A.
pullulans.
The results from the sequence analysis of the D1/D2
and ITS loci were almost entirely concordant, with the
concordance rate, calculated as percent agreement be-
tween paired results, of 94.3% (33/35 cases). The only
discrepant results were from 2 isolates designated 69.09.
IV. and 1.11.II., identified by D1/D2 sequencing as M.
sympodialis and M. globosa, respectively. Whereas the
former isolate had previously been identified (both by
PCR-RFLP analysis and ITS sequencing) as M. slooffiae,
the latter had initially been recognized as a mixture of
M. globosa and M. restricta (upon PCR-RFLP analysis),
with the presence of only M. restricta confirmed by ITS
sequencing. Based on the combined ITS and D1/D2 se-
quence analysis, those 2 isolates were considered to rep-
resent mixtures of two Malassezia species, that is M.
slooffiae and M. sympodialis (69.09.IV.) and M. globosa
and M. restricta (1.11.II.).
Comparison of PCR-RFLP analysis and PCR-sequencing
analysis
Concordance of the species identification results by
using PCR-RFLP analysis and PCR-sequencing analysis
was 85.7% (30/35 cases). Two isolates identified, upon
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II.), were identified as C. diffluens (8.11.III.) and A. pull-
ulans (10.11.II.) with PCR-sequencing. Another 2 iso-
lates initially recognized as M. furfur (45.08.III.) and M.
slooffiae (69.09.IV.) were re-identified as M. sympodialis
and a mixture of M. slooffiae and M. sympodialis, ac-
cordingly. For one isolate (20.09.IV.) being a mixture of
M. furfur and M. sympodialis, as demonstrated by PCR-
RFLP, only the presence of M. furfur was confirmed by
sequence analysis.
Comparison of phenotypic and molecular methods
The results of phenotypic and molecular identification
methods showed a concordance rate of 65.7% (23/35
cases). Twelve (34.3%) isolates produced discrepant re-
sults. These included 6M. sympodialis isolates, which by
phenotypic methods had initially been identified as M.
slooffiae (in 3 cases), M. obtusa (2 cases), and M. furfur
(one case), as well as 6 mixed-species isolates. Of the lat-
ter, morphological and biochemical tests correctly identi-
fied one of 2 co-occurring species in 5 cases. One isolate
recognized as a mixture of M. sympodialis and C. dif-
fluens had previously been identified as M. furfur, based
on the physiological testing.
Overall, among the isolates under investigation, 29
(82.9%) were identified as homogenous species, namely
M. sympodialis (24; 68.6%), M. furfur (3; 8.6%), M. glo-
bosa (1; 2.9%), and M. slooffiae (1; 2.9%). The remaining
6 (17.1%) isolates were demonstrated heterogeneous, be-
ing mixtures of two species; 2 isolates consisted of M.
furfur and M. sympodialis, (20.09.IV.; 45.08.III.), one iso-
late contained M. sympodialis and M. slooffiae (69.09.
IV.), and the other one M. globosa and M. restricta
(1.11.II.). Two isolates were mixtures of M. sympodialis
and a non-Malassezia species, that is either C. diffluens
(8.11.III.) or A. pullulans (10.11.II.).
Drug susceptibility testing
Evaluation of drug susceptibility of Malassezia spp. to 6
antifungal drugs was conducted on 19 isolates represent-
ing all Malassezia isolates cultured from 4 patients with
AD, 4 patients with PS, and 4 healthy volunteers, ran-
domly selected within each subject groups. All isolates
examined were found susceptible to all 6 antifungals
tested (Table 3). Six (31.6%) isolates showed intermedi-
ate susceptibility to at least one drug; 2 isolates (one of
M. furfur (45.08.II.) and the other of M. sympodialis
(12.09.IV.)) were intermediately susceptible to ECZ; one
isolate, identified as a mixture of M. slooffiae and M.
sympodialis (69.09.IV.) was intermediately susceptible to
MNZ. Two isolates, identified as mixtures of M. furfur
and M. sympodialis, and designated 45.08.III. and 20.09.
IV. were intermediately susceptible to 2 (KTZ + ECZ)
and 3 (KTZ + ECZ +MNZ) drugs, respectively. A three-drug intermediate susceptible pattern (KTZ + ECZ +
MNZ) was also observed in one M. furfur isolate (43.08.
II.). Overall, based on the inhibition zone diameter
values, the more susceptible isolates included M. sloof-
fiae and most of the M. sympodialis isolates, whereas
the least susceptible isolates were represented by M. fur-
fur and M. furfur co-cultured with M. sympodialis
(Table 3).
Distribution of Malassezia species
The final species identification, based on the molecular
data, was used to determine the frequency distribution
of Malassezia species among different subject groups.
Of the culture-positive samples from AD patients, all
yielded M. sympodialis isolates. These were homoge-
neous cultures in all cases, except one, where a mixed
culture of M. sympodialis and C. diffluens was obtained.
Among the PS patients, 2 Malassezia species were iden-
tified, with M. sympodialis having been isolated from 7
(out of 9) samples of 5 (out of 6) patients, and M. furfur –
from 5 samples of 4 patients. Those 2 species co-occurred
in 2 samples from 2 different patients. A specimen from
one psoriatic patient yielded a co-culture of M. sympodia-
lis and A. pullulans. In the control group M. sympodialis
was the most frequently observed, having been isolated
from a total of 10 (out of 13) skin samples of all healthy
subjects, including every sample of 4 of them. Malassezia
globosa and M. slooffiae were isolated from 2 samples of
single subjects either alone or in combination with M.
restricta and M. sympodialis, respectively.
Overall, M. sympodialis was the predominant species
in all 3 subject groups, having been cultured from a total
of 29 (82.9%) skin samples collected from all subjects
under the study except one PS patient. The second most
common species was M. furfur, recovered from 5 speci-
mens of 4 PS patients. Malassezia globosa and M. sloof-
fiae were isolated from 2 samples, each, originating
from 2 normal individuals. Two non-Malassezia species,
namely C. diffluens and A. pullulans , both co-occurring
with M. sympodialis, were recovered from a patient with
AD and a patient with PS, respectively.
Statistical analysis of the data showed that the only
significant association was that isolation of M. sympodia-
lis alone was more frequent among AD patients and
healthy volunteers, as opposed to PS patients, for whom
isolation of other Malassezia and non-Malassezia spe-
cies, either alone or mixed (also with M. sympodialis)
was reported (P < 0.03).
Discussion
Although several Malassezia species have been associ-
ated with various dermatological diseases, the exact
pathological role of individual species remains obscured.
An essential and still open question is whether there
Table 3 Results of drug susceptibility testing of 19 Malassezia sp. isolates, as determined by Neo-Sensitabs assay
Malassezia sp. (no.) Antifungal druga

























M. sympodialis (13) 28 S (13) 43 S (13) 33.9 S (13) 36.5 S (13) 24.5 S (12) 26.5 S (13)
17 I (1)
M. furfur (2) 23 S (2) 36 S (2) 30 S (1) 29 S (2) 15.5 I (2) 20 S (1)
25 I (1) 17 I (1)
M. furfur +M.
sympodialis (2)
22.5 S (2) 39 S (2) 25.5 I (2) 28.5 S (2) 14.5 I (2) 20 S (1)
15 I (1)
M. slooffiae (1) 30 S (1) 45 S (1) 35 S (1) 45 S (1) 30 S (1) 20 S (1)
M. slooffiae +M.
sympodialis (1)
30 S (1) 40 S (1) 40 S (1) 40 S (1) 30 S (1) 16.5 I (1)
aCPO, ciclopirox; FLZ, fluconazole; KTZ, ketoconazole; ITZ, itraconazole; ECZ, econazole; MNZ, miconazole; number of isolates are given in brackets.
bInhibition zone diameter mean value [mm] (each isolated was tested twice).
cSusceptibility categorization (S, susceptible; I, intermediate; R, resistant) based on the following criteria: CPO, ECZ, MNZ: S, ≥ 20; I, 12–19; R, ≤ 11; FLZ: S, ≥ 22;
I, 15–21; R, ≤ 14; ITZ: S, ≥ 16; I, 10–15; R, < 10; KTZ: S, ≥ 30; I, 23–29; R, ≤ 22.
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cies and various skin disorders. Other clinical questions
to be resolved include whether any of the Malassezia
species preferentially occupies certain sites of the body,
whether there are any differences in the distribution of
the yeasts between lesioned and normal-appearing skin
of patients, between adult and children, or between pa-
tients and healthy individuals, and finally whether there
is variation in the prevalence of Malassezia species de-
pending on gender, age, or geographical origin of the hu-
man host. There are now a growing number of works
addressing these issues. For instance, studies of the
Malassezia microbiota in healthy individuals consistently
indicated M. globosa and M. restricta as the predomin-
ant species, with a combined detection rate of over 50%
(in most of the studies) [7,31,32,34,35,49-51]. Whereas
the involvement of the Malassezia species in SD and PV
has been quite well recognized [35,50,52-58], the clinical
role of these fungi in AD and PS is still controversial.
The Malassezia yeasts are currently considered as con-
tributory factors to the induction and exacerbation of
both these conditions. The present study was to deter-
mine the composition of Malassezia microbiota on the
skin of patients with AD and PS, and healthy volunteers
from Poland. The choice of the study population was
driven by two facts. First, there are much less data on
the Malassezia microflora in AD and PS, than in other
Malassezia-related diseases (i.e. PV, and SD). Second,
AD and PS are the two most common chronic skin dis-
eases, whose incidence has been on the rise in recent
years in Poland. Among the Polish population, the
prevalence of AD is around 1.4% in adults, and thrice as
much (4.7%) in children aged between 3 to 16 years (but
up to 32% in infants and young children, that is aged be-
tween 0–6 years) [59,60]. Psoriasis, on the other hand, isestimated to affect up to 1 million people in Poland (ca.
2.6% of general population) [61].
The Malassezia yeasts were cultured from almost half
(48.6%) of the harvested skin samples, with the back being
most heavily colonized body site, accounting for ca. 46%
of the Malassezia cultures. The predominant Malassezia
species in two clinical groups and the healthy control
group was M. sympodialis. The recovery rate for this spe-
cies among AD patients, PS patients, and healthy subjects
was 100%, 70%, and 76.9%, respectively, and the overall re-
covery rate for M. sympodialis was 82.9%. The finding of
such a high prevalence of M. sympodialis was rather unex-
pected, since other Malassezia species have usually been
much more abundant in all three aforementioned groups,
as reported by other authors. In a study of Nakabayashi et
al., M. sympodialis was only the third most common spe-
cies in lesional skin of AD Japanese patients (7% of sam-
ples), following M. furfur (21%), and M. globosa (14%)
[50]. In a study from Sweden, M. sympodialis was absent
from lesional sites of AD patients, whereas other Malasse-
zia species (i. e. M. globosa, M. obtusa, M. restricta, and
M. slooffiae) occurred at low rates of 3-11% [62]. Two fur-
ther studies that used culture-independent, DNA-based
methods for the detection of Malassezia species, showed
M. globosa and M. restricta as the predominant species in
AD. They were detected at frequencies ranging from
87.5% to 100%, while M. sympodialis at 40.6% and 58.3%
[35,51]. However, in a Canadian study of Gupta et al., it
was M. sympodialis that predominated in AD patients,
with a detection rate of 51.5% [53]. Likewise, M. sympo-
dialis was the dominant species among Korean AD pa-
tients, yet the isolation rate was low (16.3%) [33]. Among
very few reports on the prevalence and species compos-
ition of Malassezia yeasts in PS patients, two were almost
completely negative for the presence of M. sympodialis; in
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species in PS patients was M. globosa (55%) followed by
M. slooffiae (17%) and M. restricta (10%) [63], while in a
study from Iran, M. globosa, as the commonest species in
PS (47%), was followed by M. furfur (39%) and M. restricta
(11%) [64]. Similar data were obtained from a Japanese,
culture-independent study of Takahata et al., who found
M. globosa and M. restricta as the sole two Malassezia
species in psoriatic scale samples, with similarly high de-
tection frequencies of 98% and 92%, respectively [38].
However, in another study from Japan, as well as in a
Canadian, culture-based study, M. sympodialis was found
the third (50%), after M. restricta (91%) and M. globosa
(68%) or the second (31%), after M. globosa (58%) most
frequently isolated Malassezia species from psoriatic le-
sions [53,65]. As for the healthy skin, none of the hitherto
performed studies have shown the predominance of M.
sympodialis, as that seen in the present work. This species
has usually ranked third in overall abundance among
Malassezia species colonizing normal human skin, with
the detection rate spanned from 10% to ca. 40%
[7,31,32,35,50]. Two major components of the Malassezia
biota of healthy individuals, that is M. globosa and M.
restricta were seriously underrepresented in the current
study, with an overall isolation rate of 15.4% and 7.7%, re-
spectively. The disparities between the studies, as discussed
above, in frequencies of Malassezia species isolations from
different dermatological affections and body sites may be
attributable to several factors, including geographical and
ethnic origin, clinical and demographic characteristics and
even lifestyle habits of the subjects under the study, but
also certain methodological issues, such as the use of dif-
ferent sampling techniques (swabbing, scraping) or culture
media (modified Dixon agar, Leeming-Notman agar).
However, the distribution ofMalassezia species is probably
most influenced by a method used for species identifica-
tion. Although the traditional identification schemes, based
on morphological characteristics and biochemical activ-
ities, are in many clinical laboratories the only diagnostic
methods available, they suffer from apparent limitations.
Phenotypic tests are time-consuming, labour-intensive and
often produce variable or inconclusive results, especially
for newly described species; the final result relies on
subjective interpretation by a laboratory expert. These
methods are thus successively being complemented or re-
placed by DNA-based molecular techniques, of which
PCR-RFLP analysis and PCR sequencing have most ex-
tensively been used [18,26,29-34,39-41]. Conceptually and
technically PCR sequencing is the simplest. It is also the
fastest and the most specific identification approach. An
important advantage of DNA sequencing over PCR-RFLP
is that the latter often involves a lengthy and laborious
analysis of complex banding patterns, not always lead-
ing to a conclusive result. Moreover, DNA sequencingpossesses a much higher discriminatory capacity, allow-
ing intraspecies polymorphisms to be revealed. Some
authors have already reported on the rDNA sequence
heterogeneity within various Malassezia species, prov-
ing the existence of several individual genotypes within
the species [26,39,40]. The intra-specific genetic diver-
sity was also evidenced in this study. Two types of ITS
sequences for M. sympodialis and two types of D1/2 se-
quences for M. globosa were demonstrated. Given the
ability of DNA sequencing for strain typing and its po-
tential use in phylogenetic and population genetics
studies, along with the costs of sequencing rapidly
plummeting, the method may soon become an integral
part not only of a species identification algorithm but
also of a routine epidemiological investigation.
The phenotypic and molecular identification results
were discordant in ca. 35% of cases (12/35). The reason
for this might either be the misidentification or the co-
occurrence of different Malassezia species in one cul-
ture. The latter explanation is even more likely, as in the
third of the discrepant cases, molecular methods did not
invalidate the presence of a species identified by conven-
tional phenotypic approach but only uncovered another,
co-occurring Malassezia species. This in turn relates to
the fact that the establishment of an axenic culture of a
Malassezia species, uncontaminated by other Malasse-
zia and non-Malassezia yeasts is rather challenging. A
mixture of Malassezia species may not only be present
in a clinical sample but even in a seemingly pure single
colony on a culture medium. The co-isolation of two
Malassezia species from the same specimen was re-
corded in 4 (11.4%) cases evaluated in this study. A
higher prevalence of mixed Malassezia cultures was re-
ported by other authors. For instance, in a Korean study
of Lee et al., 15% of SD patients and 21% of healthy vol-
unteers showed co-colonization of two or more Malas-
sezia species [34]. In two European studies, M. globosa,
the most commonly observed species, was associated in
culture with other Malassezia species in 18% of PV pa-
tients from Greece [52] and 40% of PV patients from
Spain [55]. Interestingly, in two cases in this study, M.
sympodialis was co-cultured with a non-Malassezia spe-
cies, namely Cryptococcus diffluens in an AD patient and
Aureobasidium pullulans in a PS patient. Finding of C.
diffluens on AD-affected skin is perfectly in line with
previous research demonstrating this species to be a fre-
quent colonizer of the skin surface of AD patients [66].
As for A. pullulans, it is a ubiquitous dematiaceous fun-
gus that has emerged as an opportunistic human patho-
gen, especially among immunocompromised patients; it
is a frequently isolated skin contaminant but rarely a
causative agent of fungemia, systemic infections and ab-
scesses in different viscera [67]. The discordance be-
tween phenotypic and molecular identification may also
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It means that in a mixed culture, the fast-growing spe-
cies, such as M. sympodialis may conceal the presence
of the slow growers, such as M. globosa, M. restrica, or
M. obtusa. This is also a possible explanation for the
overall high frequency of M. sympodialis isolations in
this study. Against this possibility is the fact that always
a selected single separated colony from a primary cul-
ture served as an inoculum for the culture used for spe-
cies identification tests. The six mixed-species cultures
represent the only cases in which a primary culture col-
ony already contained a mixture of distinct yeast species.
Nevertheless, it seems that a molecular-based but culture-
independent method would serve as a more accurate and
reliable approach for the assessment of the diversity of
Malassezia microbiota [28,35,38,51]. The use of culture-
based approach for characterizing Malassezia communi-
ties from skin samples posed a limitation to the present
study. Due to the fastidious nature of Malassezia fungi
and difficulties in culture arising therefrom, the obtained
results may understate the size and complexity (species
structure) of the Malassezia microbiota.
Culture-based methods essentially select for those spe-
cies that readily grow under the typical nutritional and
physiological conditions supported by commonly used
artificial media. These species may not represent the
most abundant or influential organisms within a given
locality [68].
There is a paucity of reports on drug resistance in
Malassezia spp., and this mainly stems from the lack of a
standardized protocol for Malassezia susceptibility testing.
The observed variability of the results from laboratory to
laboratory precludes any association of in vitro and in vivo
responses of Malassezia yeasts to antifungals. In this study,
the Neo-Sensitabs tablet diffusion assay was employed to
test the susceptibilities of selected Malassezia strains to six
drugs most widely used in the treatment of Malassezia in-
fections, that is the azoles (FLZ, ECZ, ITZ, KTZ, and
MNZ) and cyclopiroxolamine (CPO). All the analysed iso-
lates were susceptible to those compounds, albeit the tria-
zoles (FLZ and ITZ) and CPO were found to be more
active than the azole derivatives (ECZ, MNZ, and KTZ).
Noteworthy, strains of M. furfur generally appeared less
susceptible than strains of M. slooffiae or M. sympodialis,
indicating that certain Malassezia species develop mecha-
nisms of drug tolerance more easily than other species do.
Some variations between different Malassezia species in
the susceptibilities to antifungal agents were also recorded
by other authors [69,70]. Although the molecular bases of
drug resistance in Malassezia fungi are largely unknown,
there is an optimism that this will change now with an in-
creasing body of data from the whole genome sequencing
projects [71,72]. Recently, Kim et al. have demonstrated
that genetic alterations in the amino acid sequence of aputative lanosterol 14α-demethylase (CYP51) from M. glo-
bosa may be responsible for resistance to azoles by block-
ing substrate access channels of the enzyme [73].
Conclusions
To conclude, this study provides an important insight into
the species composition of Malassezia microbiota in hu-
man skin. The most important findings can be summa-
rized in three points. First, M. sympodialis was the
predominant species in both normal and pathologic (AD-
and PS-affected) skin. Furthermore, AD patients yielded
exclusively M. sympodialis isolates, whereas isolates of M.
furfur were observed only in PS patients. Whether this
mirrors any predilection of particular Malassezia species
for certain clinical conditions, and whether the overall
dominance of M. sympodialis reflects geographical specifi-
city needs to be evaluated on a much larger scale. Second,
although the overall concordance between phenotypic and
molecular methods was quite high (65%), with the dis-
cordant results being rather due to the presence of mul-
tiple species in a single culture (co-colonization) than true
misidentification, for the identification of Malassezia spe-
cies, molecular typing approach is preferred, as its results
are more reliable and straightforward. Third, all Malasse-
zia isolates were susceptible to cyclopiroxolamine and
azole drugs, with M. furfur isolates being somewhat more
drug tolerant than other Malassezia species.
Abbreviations
AD: Atopic dermatitis; AFLP: Amplified fragment length polymorphism;
BSA: Body surface area; CHS2: Chitin synthase; CLSI: Clinical and Laboratory
Standards Institute; CPO: Ciclopirox; DGGE: Denaturing gradient gel
electrophoresis; ECZ: Econazole; FLZ: Fluconazole; ITS: Internal transcribed
spacer; ITZ: Itraconazole; KTZ: Ketoconazole; MDA: Modified Dixon’s agar;
MEE: Multilocus enzyme electrophoresis; MNZ: Miconazole; NCBI: National
Center for Biotechnology Information; PASI: Psoriasis area and severity;
PCR-RFLP: PCR-based restriction fragment length polymorphism; PCR-
SSCP: PCR-based single strand confirmation polymorphism; PFGE:
Pulsed-field gel electrophoresis; PS: Psoriasis; PV: Pityriasis versicolor;
RPB1: RNA polymerase subunit 1; SCORAD: Severity scoring of atopic
dermatitis; SD: Seborrheic dermatitis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TJ participated in the design of the study, supervised all experimental
procedures, and wrote the entire manuscript. ER collected samples,
performed drug susceptibility testing, participated in the design of the study
and species identification. AZ performed the sequencing analyses. KR did the
PCR-RFLP assays. AM and JB revised the manuscript critically for important in-
tellectual content. All authors read and approved the final manuscript.
Acknowledgements
The authors are indebted to Asst. Prof. Aristea Velegraki (Department of
Microbiology, Medical School, Aristotle University of Thessaloniki,
Thessaloniki, Greece) for her kind revision of the manuscript.
Author details
1Department of Applied Microbiology, Institute of Microbiology, Faculty of
Biology, University of Warsaw, I. Miecznikowa 1, 02-096 Warsaw, Poland.
2Department of Mycology, Chair of Microbiology, Collegium Medicum,
Jagiellonian University, Cracow, Poland.
Jagielski et al. BMC Dermatology 2014, 14:3 Page 14 of 15
http://www.biomedcentral.com/1471-5945/14/3Received: 4 September 2013 Accepted: 1 March 2014
Published: 7 March 2014References
1. Gao Z, Perez-Perez GI, Chen Y, Blaser MJ: Quantitation of major human
cutaneous bacterial and fungal populations. J Clin Microbiol 2010,
48:3575–3581.
2. Crespo-Erchiga V, Florencio VD: Malassezia yeasts and pityriasis versicolor.
Curr Opin Infect Dis 2006, 19:139–147.
3. Hay RJ: Malassezia, dandruff and seborrhoeic dermatitis: an overview.
Br J Dermatol 2011, 165:2–8.
4. Amado Y, Patiño-Uzcátegui A, de García MC C, Tabima J, Motta A, Cárdenas
M, Bernal A, Restrepo S, Celis A: Seborrheic dermatitis: predisposing
factors and ITS2 secondary structure for Malassezia phylogenic analysis.
Med Mycol 2013, 51:868–875.
5. Kanda N, Tani K, Enomoto U, Nakai K, Watanabe S: The skin fungus-
induced Th-1 and Th-2 related cytokine, chemokine and psostaglandin
E2 production in peripheral blood mononuclear cells from patients with
atopic dermatitis and psoriasis vulgaris. Clin Exp Allerg 2002, 32:1243–1250.
6. Baroni A, Paoletti I, Ruocco E, Agozzino M, Tufano MA, Donnarumma G:
Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1,
integrin, and HSP70 expression in human keratinocytes and in the skin
of psoriasis-affected patients. J Cut Pathol 2004, 31:35–42.
7. Ko JH, Lee YW, Choe YB, Ahn KJ: Epidemiologic study of Malassezia yeasts
in patients with Malassezia folliculitis by 26S rDNA PCR-RFLP analysis.
Ann Dermatol 2011, 23:177–184.
8. Zhao Y, Li L, Wang JJ, Kang KF, Zhang QQ: Cutaneous malasseziasis: four
case reports of atypical dermatitis and onychomycosis caused by
Malassezia. Int J Dermatol 2010, 49:141–145.
9. Bernier V, Weill FX, Hirigoyen V, Elleau C, Feyler A, Labrèze C, Sarlangue J,
Chène G, Couprie B, Taïeb A: Skin colonization by Malassezia species in
neonates. A prospective study and relationship with neonatal cephalic
pustulosis. Arch Dermatol 2002, 138:215–218.
10. Ginarte M, Fabeiro JM, Toribio J: Confluent and reticulated papillomatosis
(Gougerot-Carteaud) successfully treated with tacalcitol. J Dermatolog
Treat 2002, 13:27–30.
11. Chryssanthou E, Broberger U, Petrini B: Malassezia pachydermatis
fungaemia in a neonatal intensive care unit. Acta Paediatr 2001, 90:323–327.
12. Archer-Dubon C, Icaza-Chivez ME, Orozco-Topete R, Reyes E, Baez-Martinez
R, Ponce de León S: An epidemic outbreak of Malassezia folliculitis in
three adult patients in an intensive care unit: a previously unrecognized
nosocomial infection. Int J Dermatol 1999, 38:453–456.
13. Guého E, Midgley G, Guillot J: The genus Malassezia with description of
four new species. Antonie Van Leeuwenhoek 1996, 69:337–355.
14. Sugita T, Takashima M, Shinoda T, Suto H, Unno T, Tsuboi R, Ogawa H,
Nishikawa A: New yeast species, Malassezia dermatis, isolated from
patients with atopic dermatitis. J Clin Microbiol 2002, 40:1363–1367.
15. Sugita T, Takashima M, Kodama M, Tsuboi R, Nishikawa A: Description of a
new yeast species, Malassezia japonica, and its detection in patients with
atopic dermatitis and healthy subjects. J Clin Microbiol 2003, 41:4695–4699.
16. Sugita T, Tajima M, Takashima M, Amaya M, Saito M, Tsuboi R, Nishikawa A:
A new yeast, Malassezia yamatoensis, isolated from a patient with
seborrheic dermatitis, and its distribution in patients and healthy
subjects. Microbiol Immunol 2004, 48:579–583.
17. Hirai A, Kano R, Makimura K, Duarte ER, Hamdan JS, Lachance MA,
Yamaguchi H, Hasegawa A: Malassezia nana sp. nov., a novel lipid-
dependent yeast species isolated from animals. Int J Syst Evol Microbiol
2004, 54:623–627.
18. Cabañes FJ, Theelen B, Castellá G, Boekhout T: Two new lipid-dependent
Malassezia species from domestic animals. FEMS Yeast Res 2007,
7:1064–1076.
19. Cabañes FJ, Vega S, Castellá G: Malassezia cuniculi sp. nov., a novel yeast
species isolated from rabbit skin. Med Mycol 2011, 49:40–48.
20. Casagrande BF, Flückiger S, Linder MT, Johansson C, Scheynius A, Crameri R,
Schmid-Grendelmeier P: Sensitization to the yeast Malassezia sympodialis
is specific for extrinsic and intrinsic atopic eczema. J Invest Dermatol 2006,
126(11):2414–2421.
21. Scheynius A, Johansson C, Buentke E, Zargari A, Linder MT: Atopic eczema/
dermatitis syndrome and Malassezia. Int Arch Allergy Immunol 2002,
127:161–169.22. Guého E, Batra R, Boekhout T: The genus Malassezia Baillon (1889). In The
Yeasts, a Taxonomic Study. 5th edition. Edited by Kurtzman CP, Fell JW,
Boekhout T. Amsterdam: Elsevier; 2011:1807–1833.
23. Boekhout T, Kamp M, Guého E: Molecular typing of Malassezia species
with PFGE and RAPD. Med Mycol 1998, 36:365–372.
24. Senczek D, Siesenop U, Böhm KH: Characterization of Malassezia species
by means of phenotypic characteristics and detection of electrophoretic
karyotypes by pulsed-field gel electrophoresis (PFGE). Mycoses 1999,
42:409–414.
25. Theelen B, Silvestri M, Guého E, van Belkum A, Boekhout T: Identification
and typing of Malassezia yeasts using amplified fragment length
polymorphism (AFLP), random amplified polymorphic DNA (RAPD) and
denaturing gradient gel electrophoresis (DGGE). FEMS Yeast Res 2001,
1:79–86.
26. Gupta AK, Boekhout T, Theelen B, Summerbell R, Batra R: Identification and
typing of Malassezia species by amplified fragment length
polymorphism and sequence analyses of the internal transcribed spacer
and large-subunit regions of ribosomal DNA. J Clin Microbiol 2004,
42:4253–4260.
27. Midreuil F, Guillot J, Guého E, Renaud F, Mallié M, Bastide JM: Genetic
diversity in the yeast species Malassezia pachydermatis analysed by
multilocus enzyme electrophoresis. Int J Syst Bacteriol 1999, 49:1287–1294.
28. Gaitanis G, Velegraki A, Frangoulis E, Mitroussia A, Tsigonia A, Tzimogianni A,
Katsambas A, Legakis NJ: Identification of Malassezia species from patient
skin scales by PCR-RFLP. Clin Microbiol Infect 2002, 8:162–173.
29. Guillot J, Deville M, Berthelemy M, Provost F, Guého E: A single PCR-
restriction endonuclease analysis for rapid identification of Malassezia
species. Lett Appl Microbiol 2000, 31:400–403.
30. Mirhendi H, Makimura K, Zomorodian K, Yamada T, Sugita T, Yamaguchi H:
A simple PCR-RFLP method for identification and differentiation of 11
Malassezia species. J Microbiol Methods 2005, 61:281–284.
31. Jang SJ, Lim SH, Ko JH, Oh BH, Kim SM, Song YC, Yim SM, Lee YW, Choe YB,
Ahn KJ: The investigation on the distribution of Malassezia yeasts on the
normal Korean skin by 26S rDNA PCR-RFLP. Ann Dermatol 2009, 21:18–26.
32. Oh BH, Song YC, Lee YW, Choe YB, Ahn KJ: Comparison of nested PCR and
RFLP for identification and classification of Malassezia yeasts from
healthy human skin. Ann Dermatol 2009, 21:352–357.
33. Yim SM, Kim JY, Ko JH, Lee YW, Choe YB, Ahn KJ: Molecular analysis of
Malassezia microflora on the skin of the patients with atopic dermatitis.
Ann Dermatol 2010, 22:41–47.
34. Lee YW, Byun HJ, Kim BJ, Kim DH, Lim YY, Lee JW, Kim MN, Kim D, Chun YJ, Mun
SK, Kim CW, Kim SE, Hwang JS: Distribution of Malassezia species on the scalp
in Korean seborrheic dermatitis patients. Ann Dermatol 2011, 23:156–161.
35. Tajima M, Sugita T, Nishikawa A, Tsuboi R: Molecular analysis of Malassezia
microflora in seborrheic dermatitis patients: comparison with other
diseases and healthy subjects. J Invest Dermatol 2008, 128:345–351.
36. Morishita N, Sei Y, Sugita T: Molecular analysis of Malassezia microflora
from patients with pityriasis versicolor. Mycopathologia 2006, 161:61–65.
37. Gemmer CM, DeAngelis YM, Theelen B, Boekhout T, Dawson Jr TL Jr: Fast,
noninvasive method for molecular detection and differentiation of
Malassezia yeast species on human skin and application of the method
to dandruff microbiology. J Clin Microbiol 2002, 40:3350–3357.
38. Takahata Y, Sugita T, Hiruma M, Muto M: Quantitative analysis of
Malassezia in the scale of patients with psoriasis using a real-time
polymerase chain reaction assay. Br J Dermatol 2007, 157:670–673.
39. Makimura K, Tamura Y, Kudo M, Uchida K, Saito H, Yamaguchi H: Species
identification and strain typing of Malassezia species stock strains and
clinical isolates based on the DNA sequences of nuclear ribosomal
internal transcribed spacer 1 regions. J Med Microbiol 2000, 49:29–35.
40. Sugita T, Kodama M, Saito M, Ito T, Kato Y, Tsuboi R, Nishikawa A: Sequence
diversity of the intergenic spacer region of the rRNA gene of Malassezia
globosa colonizing the skin of patients with atopic dermatitis and
healthy individuals. J Clin Microbiol 2003, 41:3022–3027.
41. Kano R, Aizawa T, Nakamura Y, Watanabe S, Hasegawa A: Chitin synthase 2
gene sequence of Malassezia species. Microbiol Immunol 1999, 43:813–815.
42. Hanifin J, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm
Venereol 1980, 60:44–47.
43. European Task Force on Atopic Dermatitis: Severity scoring of atopic
dermatitis: the SCORAD index. Dermatology 1993, 186:23–31.
44. Ramsay B, Lawrence CM: Measurement of involved surface area in
patients with psoriasis. Br J Dermatol 1991, 124:565–570.
Jagielski et al. BMC Dermatology 2014, 14:3 Page 15 of 15
http://www.biomedcentral.com/1471-5945/14/345. Fredriksson T, Pettersson U: Oral treatment of pustulosis palmo-plantaris
with a new retinoid, Ro 10–9359. Dermatologica 1979, 158:60–64.
46. Clinical and Laboratory Standards Institute/National Committee for Clinical
Laboratory Standards: Method for Antifungal Disk Diffusion Susceptibility
Testing of Yeasts: Approved Guideline, Document M44-A. Wayne, PA: Clinical
and Laboratory Standards Institute; 2000.
47. Kurtzman CP, Fell JW, Boekhout T, Robert V: Methods for isolation,
phenotypic characterization, and maintenance of yeasts. In The Yeasts, a
Taxonomic Study. 5th edition. Edited by Kurtzman CP, Fell JW, Boekhout T.
Amsterdam: Elsevier; 2010:87–111.
48. Ashbee HR, Evans EGV: Immunology of diseases associated with
Malassezia species. Clin Microbiol Rev 2002, 15:21–57.
49. Gupta AK, Kohli Y: Prevalence of Malassezia species on various body sites
in clinically healthy subjects representing different age groups.
Med Mycol 2004, 42:35–42.
50. Nakabayashi A, Sei Y, Guillot J: Identification of Malassezia species isolated
from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis
versicolor and normal subjects. Med Mycol 2000, 38:337–341.
51. Sugita T, Suto H, Unno T, Tsuboi R, Ogawa H, Shinoda T, Nishikawa A:
Molecular analysis of Malassezia microflora on the skin of atopic
dermatitis patients and healthy subjects. J Clin Microbiol 2001,
39:3486–3490.
52. Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A:
Distribution of Malassezia species in pityriasis versicolor and seborrhoeic
dermatitis in Greece. Typing of the major pityriasis versicolor isolate
M. globosa. Br J Dermatol 2006, 154:854–859.
53. Gupta AK, Kohli Y, Summerbell RC, Faergemann J: Quantitative culture of
Malassezia species from different body sites of individuals with or
without dermatoses. Med Mycol 2001, 39:243–251.
54. Affes M, Salah SB, Makni F, Sellami H, Ayadi A: Molecular identification of
Malassezia species isolated from dermatitis affections. Mycoses 2009,
52:251–256.
55. Crespo Erchiga V, Ojeda Martos A, Vera Casaño A, Crespo Erchiga A,
Sanchez Fajardo F: Malassezia globosa as the causative agent of pityriasis
versicolor. Br J Dermatol 2000, 143:799–803.
56. Chaudhary R, Singh S, Banerjee T, Tilak R: Prevalence of different
Malassezia species in pityriasis versicolor in central India.
Indian J Dermatol Venereol Leprol 2010, 76:159–164.
57. Tarazooie B, Kordbacheh P, Zaini F, Zomorodian K, Saadat F, Zeraati H,
Hallaji Z, Rezaie S: Study of the distribution of Malassezia species in
patients with pityriasis versicolor and healthy individuals in Tehran, Iran.
BMC Dermatol 2004, 4:5.
58. Ramadán S, Sortino M, Bulacio L, Marozzi ML, López C, Ramos L: Prevalence
of Malassezia species in patients with pityriasis versicolor in Rosario,
Argentina. Rev Iberoam Micol 2012, 29:14–19.
59. Kupryś-Lipińska I, Elgalal A, Kuna P: Epidemiology of atopic dermatitis in
general population of the Lodz province’s citizens. Pneumonol Alergol Pol
2009, 77:145–151.
60. Frankowska J, Kamer B, Trznadel-Budźko E, Rotsztejn H: The estimation of
atopic dermatitis in infants and small children in general practitioner’s
practice – own observations. Wiad Lek 2011, 64:176–180.
61. Neneman A, Adamski Z: Clinical and epidemiological systemic disorders
in psoriasis patients. Forum Med Rodz 2009, 3:447–453.
62. Sandström Falk MH, Tengvall Linder M, Johansson C, Bartosik J, Bäck O,
Särnhult T, Wahlgren CF, Scheynius A, Faergemann J: The prevalence of
Malassezia yeasts in patients with atopic dermatitis, seborrhoeic
dermatitis and healthy controls. Acta Derm Venereol 2005, 85:17–23.
63. Prohić A: Identification of Malassezia species isolated from scalp skin of
patients with psoriasis and healthy subjects. Acta Dermatovenerol Croat
2003, 11:10–16.
64. Zomorodian K, Mirhendi H, Tarazooie B, Zeraati H, Hallaji Z, Balighi K:
Distribution of Malassezia species in patients with psoriasis and healthy
individuals in Tehran. J Cutan Pathol 2008, 35:1027–1031.
65. Amaya M, Tajima M, Okubo Y, Sugita T, Nishikawa A, Tsuboi R: Molecular
analysis of Malassezia microflora in the lesional skin of psoriasis patients.
J Dermatol 2007, 34:619–624.
66. Sugita T, Saito M, Ito T, Kato Y, Tsuboi R, Takeuchi S, Nishikawa A: The
basidiomycetous yeasts Cryptococcus diffluens and C. liquefaciens
colonize the skin of patients with atopic dermatitis. Microbiol Immunol
2003, 47:945–950.67. Chan GF, Puad MS, Chin CF, Rashid NA: Emergence of Aureobasidium
pullulans as human fungal pathogen and molecular assay for future
medical diagnosis. Folia Microbiol (Praha) 2011, 56:459–467.
68. Grice EA, Segre JA: The skin microbiome. Nat Rev Microbiol 2011, 9:244–253.
69. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC: In vitro susceptibility of
the seven Malassezia species to ketoconazole, voriconazole, itraconazole
and terbinafine. Br J Dermatol 2000, 142:758–765.
70. Hammer KA, Carson CF, Riley TV: In vitro activities of ketoconazole,
econazole, miconazole and Melaleuca alternifolia (tea tree) oil against
Malassezia species. Antimicrob Agents Chemother 2000, 44:67–69.
71. Xu J, Saunders CW, Hu P, Grant RA, Boekhout T, Kuramae EE, Kronstad JW,
DeAngelis YM, Reeder NL, Johnstone KR, Leland M, Fieno AM, Begley WM,
Sun Y, Lacey MP, Chaudhary T, Keough T, Chu L, Sears R, Yuan B, Dawson
TL Jr: Dandruff-associated Malassezia genomes reveal convergent and
divergent virulence traits shared with plant and human fungal
pathogens. Proc Natl Acad Sci USA 2007, 104:18730–18735.
72. Gioti A, Nystedt B, Li W, Xu J, Andersson A, Averette AF, Münch K, Wang X,
Kappauf C, Kingsbury JM, Kraak B, Walker LA, Johansson HJ, Holm T, Lehtiö
J, Stajich JE, Mieczkowski P, Kahmann R, Kennell JC, Cardenas ME,
Lundeberg J, Saunders CW, Boekhout T, Dawson TL, Munro CA, de Groot
PWJ, Butler G, Heitman J, Scheynius A: Genomic insights into the atopic
eczema-associated skin commensal yeast Malassezia sympodialis. mBio
2013, 4:16. 00572–12.
73. Kim D, Lim YR, Ohk SO, Kim BJ, Chun YJ: Functional expression and
characterization of CYP51 from dandruff-causing Malassezia globosa.
FEMS Yeast Res 2011, 11:80–87.
doi:10.1186/1471-5945-14-3
Cite this article as: Jagielski et al.: Distribution of Malassezia species on
the skin of patients with atopic dermatitis, psoriasis, and healthy
volunteers assessed by conventional and molecular identification methods.
BMC Dermatology 2014 14:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
